Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker

Pyrotinib, a novel irreversible epidermal growth factor receptor dual tyrosine kinase inhibitor, is mainly (about 90%) eliminated through cytochrome P450 (CYP) 3A mediated metabolism in vivo. Meanwhile, genotype is a key factor affecting pyrotinib clearance and 4β-hydroxycholesterol is an endogenous...

Full description

Bibliographic Details
Main Authors: Miao Zhang, Zhiheng Yu, Xueting Yao, Zihan Lei, Kaijing Zhao, Wenqian Wang, Xue Zhang, Xijing Chen, Dongyang Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
pyrotinib
PBPK model
clinical trial design
drug-drug interaction
4βhydroxycholesterol
genotype
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.972411/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.972411/full

Similar Items